Xeris Pharmaceuticals Inc (XERS)
Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological disorders. Its marketed products include Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia in pediatric and adult patients; Keveyis, used in primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for adults with endogenous hypercortisolemia associated with Cushing’s syndrome. The company is also advancing XP-8121, a once-weekly subcutaneous levothyroxine injection, which is in phase 3 testing for hypothyroidism. Incorporated in 2005, Xeris Biopharma is headquartered in Chicago, Illinois. The listed security is common stock on the NASDAQ exchange under the symbol XERS.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-XERS
|
$7.62
|
-12.8% Downside
|
Fair
|
$11.29
|
29.2% Upside
|
Undervalued
|
Great
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
131.5x
|
121.4x
|
5.0x
|
1.559 B
|
1.726 B
|
14.2%
|
96.5%
|
1.3
|
—
|
395.7%
|
